Lipton R B, Stewart W F, Ryan R E, Saper J, Silberstein S, Sheftell F
Department of Neurology, Albert Einstein College of Medicine, Montefiore Headache Unit, Bronx, NY 10467, USA.
Arch Neurol. 1998 Feb;55(2):210-7. doi: 10.1001/archneur.55.2.210.
To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain.
Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies.
Private practice, referral centers, and general community.
Migraineurs with moderate or severe headache pain who met International Headache Society diagnostic criteria for migraine with aura or without aura. The most severely disabled segment of migraineurs, including those whose attacks usually required bed rest, or who vomited 20% or more of the time, were excluded. Of the 1357 enrolled patients, 1250 took study medication and 1220 were included in the efficacy-evaluable data set.
Two tablets of the nonprescription combination of acetaminophen, aspirin, and caffeine or placebo taken orally as a single-dose treatment of 1 eligible acute migraine attack.
Pain intensity difference from baseline; percentage of patients with pain reduced to mild or none.
Significantly greater reductions in migraine headache pain intensity 1 to 6 hours after dose were seen in patients taking the acetaminophen, aspirin, and caffeine combination than in those taking placebo in each of the 3 studies. Pain intensity was reduced to mild or none 2 hours after dose in 59.3% of the 602 drug-treated patients compared with 32.8% of the 618 placebo-treated patients (P< .001; 95% confidence interval [CI], 55%-63% for drug, 29%-37% for placebo); at 6 hours after dose, 79% vs 52%, respectively, had pain reduced to mild or none (P<.001; 95% CI, 75%-82% vs 48%-56%). In addition, by 6 hours after dose, 50.8% of the drug-treated patients were pain free compared with 23.5% of the placebo-treated patients (P<.001; 95% CI, 47%-55% for drug, 20%-27% for placebo). Other migraine headache characteristics, such as nausea, photophobia, phonophobia, and functional disability, were significantly improved 2 to 6 hours after treatment with the acetaminophen, aspirin, and caffeine combination compared with placebo (P< or =.01).
The nonprescription combination of acetaminophen, aspirin, and caffeine was highly effective for the treatment of migraine headache pain as well as for alleviating the nausea, photophobia, phonophobia, and functional disability associated with migraine attacks. This drug combination also has an excellent safety profile and is well tolerated.
评估对乙酰氨基酚、阿司匹林和咖啡因的非处方复方制剂缓解偏头痛疼痛的有效性。
三项双盲、随机、平行组、单剂量、安慰剂对照研究。
私人诊所、转诊中心和普通社区。
符合国际头痛协会伴先兆或不伴先兆偏头痛诊断标准的中度或重度头痛的偏头痛患者。排除偏头痛患者中残疾最严重的部分,包括那些发作时通常需要卧床休息或呕吐时间达20%或更多的患者。在1357名入组患者中,1250名服用了研究药物,1220名被纳入疗效可评估数据集。
口服两片对乙酰氨基酚、阿司匹林和咖啡因的非处方复方制剂或安慰剂,作为对1次符合条件的急性偏头痛发作的单剂量治疗。
与基线相比的疼痛强度差异;疼痛减轻至轻度或消失的患者百分比。
在三项研究中的每一项中,服用对乙酰氨基酚、阿司匹林和咖啡因复方制剂的患者在服药后1至6小时偏头痛疼痛强度的降低幅度均显著大于服用安慰剂的患者。在602名接受药物治疗的患者中,59.3%在服药后2小时疼痛减轻至轻度或消失,而在618名接受安慰剂治疗的患者中这一比例为32.8%(P<0.001;95%置信区间[CI],药物组为55%-63%,安慰剂组为29%-37%);在服药后6小时,分别为79%和52%的患者疼痛减轻至轻度或消失(P<0.001;95%CI,药物组为75%-82%,安慰剂组为48%-56%)。此外,在服药后6小时,50.8%接受药物治疗的患者无痛,而接受安慰剂治疗的患者中这一比例为23.5%(P<0.001;95%CI,药物组为47%-55%,安慰剂组为20%-27%)。与安慰剂相比,在服用对乙酰氨基酚、阿司匹林和咖啡因复方制剂治疗后2至6小时内,其他偏头痛特征,如恶心、畏光、畏声和功能障碍均有显著改善(P≤0.01)。
对乙酰氨基酚、阿司匹林和咖啡因的非处方复方制剂对治疗偏头痛疼痛以及缓解与偏头痛发作相关的恶心、畏光、畏声和功能障碍非常有效。这种复方制剂还具有良好的安全性,耐受性良好。